Alcoholic Deaddiction treatment

Reading File

Now let me search the medical library and PubMed in parallel for comprehensive coverage.

Finding Sources

Searching PubMed

"alcohol use disorder"[MeSH Terms] AND "treatment"[MeSH Terms]

Good results. Let me now read the most relevant textbook sections - particularly from Kaplan & Sadock's, Maudsley Guidelines, Harrison's, and Goldman-Cecil.

Finding Sources

Searching PubMed

"alcohol use disorder" AND pharmacotherapy

Excellent. Now let me read the most relevant textbook sections simultaneously.

Reading File

Excellent data from multiple sources. Let me also check the Maudsley Guidelines and Kaplan & Sadock for psychosocial and additional pharmacotherapy details.

Reading File

Finding Sources

I now have comprehensive information from multiple authoritative sources. Let me compile the full answer.

Alcoholic Deaddiction Treatment (Alcohol Use Disorder - AUD)

Treatment of AUD is structured in two major phases: (1) Detoxification/Withdrawal Management and (2) Relapse Prevention / Maintenance, supported throughout by psychosocial interventions.

Phase 1: Detoxification and Withdrawal Management

Severity Assessment

The Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) is the standard tool to grade withdrawal severity and guide treatment. It scores 10 items (tremor, agitation, nausea, anxiety, sweating, headache, perceptual disturbances, orientation) - scores >15 indicate severe withdrawal.

Withdrawal Spectrum

Stage	Onset	Features
Minor symptoms	6-12 hrs	Anxiety, tremor, insomnia, sweating
Seizures	12-48 hrs	Generalized tonic-clonic (usually single)
Alcoholic hallucinosis	12-24 hrs	Visual/auditory hallucinations; clear sensorium
Delirium Tremens (DT)	48-96 hrs	Confusion, autonomic instability, hyperthermia - mortality 5-15% if untreated

Pharmacotherapy for Withdrawal

Benzodiazepines - First Line

Preferred agents: diazepam (long-acting, smooth tapering) or chlordiazepoxide
For liver disease: oxazepam or lorazepam (no active metabolites)
Two dosing approaches:
- Fixed schedule - standing dose + PRN: safer for severe/unpredictable withdrawal
- Symptom-triggered (CIWA-guided): reduces total benzodiazepine use, preferred in monitored settings
Adjuncts: beta-blockers (atenolol, propranolol), alpha-2 agonists (clonidine), gabapentin (up to 1200 mg/day), carbamazepine - these improve autonomic symptoms but do NOT replace benzodiazepines for seizure prevention

Thiamine (Vitamin B1)

Mandatory: 250-500 mg IV/IM for 3-5 days, then 100-250 mg orally daily
Prevents Wernicke's encephalopathy (confusion, ophthalmoplegia, ataxia)
Always give thiamine before glucose to avoid precipitating encephalopathy

Setting

Mild-moderate withdrawal - outpatient with close follow-up is safe
Severe withdrawal, prior DT/seizures, significant comorbidities, failed outpatient - inpatient management

Phase 2: Relapse Prevention Pharmacotherapy

The US FDA has approved three medications for AUD maintenance treatment. All should be combined with psychosocial support.

1. Naltrexone (ReVia - oral; Vivitrol - IM monthly)

Mechanism: Opioid receptor antagonist - blocks the reward/euphoria associated with alcohol, reduces craving
Dose: 50 mg/day orally; 380 mg IM monthly (extended-release)
Key point: Injectable naltrexone has greater efficacy than oral due to better adherence
Contraindications: Active opioid use, hepatic failure, acute hepatitis
ADEs: Nausea, hepatotoxicity (dose-dependent), insomnia
Best suited for patients who want to reduce or stop drinking, especially those with strong cravings

2. Acamprosate (Campral)

Mechanism: Modulates glutamate (NMDA) and GABA activity, reducing the hyperexcitability of protracted abstinence; reduces urge to drink
Dose: 666 mg TID (three times daily)
Key point: Does NOT produce aversive reaction; preferred in outpatient settings
Renal excretion - safe in liver disease but requires dose adjustment in renal impairment
No pharmacokinetic interaction with disulfiram or naltrexone, but coadministration with naltrexone does increase acamprosate levels slightly
Best for patients who have already achieved abstinence and want to maintain it

3. Disulfiram (Antabuse)

Mechanism: Irreversibly inhibits aldehyde dehydrogenase, causing acetaldehyde accumulation (up to 10x normal) when alcohol is consumed
Reaction: Flushing, nausea, vomiting, headache, tachycardia, hypotension - begins within minutes; lasts 30 min to 2 hrs
Dose: 250-500 mg/day orally (single daily dose)
Half-life: 60-120 hrs - effects persist 1-2 weeks after stopping
Contraindications: Significant cardiac/pulmonary disease, severe hepatic disease, brain damage, seizure disorder, psychosis, pregnancy
ADEs: Fatal reactions (cardiovascular collapse, MI, convulsions) if >500 mg/day and >3 oz alcohol consumed
More commonly used in inpatient/supervised settings due to compliance issues
Should always be combined with psychotherapy and AA

Combination Therapy

Acamprosate + naltrexone can be used together when monotherapy is inadequate
Naltrexone + disulfiram combination has shown modest efficacy in patients with comorbid psychiatric disorders

Off-Label / Emerging Agents

Drug	Evidence
Topiramate	Reduces alcohol consumption; off-label but growing evidence
Gabapentin	Reduces craving and withdrawal anxiety; useful bridge drug
Nalmefene	Opioid antagonist (similar to naltrexone); used in Europe
Baclofen	GABA-B agonist; high-dose (50-150 mg/day) shows promise, especially in liver disease
GLP-1 receptor agonists (semaglutide, etc.)	Emerging evidence from recent 2024-2025 systematic reviews [PMID 39288591]
Psilocybin	Early-phase trials for substance use disorders [PMID 40245969]

Phase 3: Psychosocial Interventions (Integral to All Phases)

These are not optional - pharmacotherapy is significantly more effective when combined with behavioral support:

Approach	Description
Motivational Enhancement Therapy (MET)	Strengthens motivation to change; helps patients identify their own reasons for sobriety
Cognitive Behavioral Therapy (CBT)	Teaches coping skills to identify and manage triggers for alcohol use; relapse prevention strategies
12-Step Facilitation (AA)	Structured peer support; abstinence-focused; "Alcoholics Anonymous"; open/closed meeting formats; anonymity guaranteed
SMART Recovery	Non-12-step, secular, science-based alternative to AA
Brief Interventions (FRAMES model)	Effective in primary care/ED settings for hazardous drinkers not yet dependent

Treatment Intensity / Level of Care

Based on ASAM (American Society of Addiction Medicine) criteria:

Outpatient (OPT): mild AUD, strong support system, no serious comorbidities
Intensive Outpatient Program (IOP): 9+ hrs/week; moderate AUD
Partial Hospitalization (PHP): daily programming without overnight stay
Residential/Inpatient: severe AUD, failed outpatient, DT risk, no safe housing, serious psychiatric comorbidity

Comorbidities to Address

Depression/Anxiety: Very common comorbidities; SSRIs may help but treat the AUD first - many psychiatric symptoms improve with sobriety
Wernicke-Korsakoff Syndrome: Thiamine replacement + abstinence
Alcoholic liver disease: Disulfiram is contraindicated; naltrexone requires LFT monitoring; acamprosate is preferred
ADHD: Avoid stimulants in active/chronic AUD

Recent Evidence (2023-2026)

A landmark 2023 JAMA systematic review and meta-analysis (McPheeters et al., PMID 37934220) confirmed:

Both naltrexone and acamprosate significantly reduce return to drinking compared to placebo
Naltrexone also reduces heavy drinking days
Evidence for disulfiram is mixed due to compliance issues

Emerging data from 2024-2025 suggests GLP-1 receptor agonists (e.g., semaglutide) may reduce alcohol craving and consumption as a novel pharmacological target [PMID 39288591].

Sources: Goldman-Cecil Medicine; Kaplan & Sadock's Synopsis & Comprehensive Textbook of Psychiatry; Textbook of Family Medicine 9e; Tintinalli's Emergency Medicine; Kaplan & Sadock's Synopsis of Psychiatry; Lippincott Pharmacology; JAMA 2023 [PMID 37934220]

This is a shared conversation. Sign in to Orris to start your own chat.